Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.
Par launches advanced formulation of Megace ES
Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.